allogeneic GM-CSF-secreting myeloma vaccine

{
  "id": "MLC-T-ONC-009897",
  "term": "allogeneic GM-CSF-secreting myeloma vaccine",
  "field": "Oncology and biomedicine",
  "definition": "An allogeneic plasma cell myeloma vaccine consisting two multiple myeloma cell lines, H929 and U266, admixed with GM-CSF-secreting K562 cells, with potential antineoplastic and immunopotentiating activities. Upon administration, the secreted GM-CSF modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells, with some specificity towards stimulation of leukocyte production, and may reverse treatment-induced neutropenia. This agent also promotes antigen presentation, upregulates antibody-dependent cellular cytotoxicity (ADCC), increases interleukin-2-mediated lymphokine-activated killer cell (LAK) function and may augment host antitumoral immunity. For safety, the myeloma cells are irradiated prior to vaccination.",
  "synonyms": [
    "allogeneic GM-CSF-secreting multiple myeloma vaccine",
    "allogeneic GVAX myeloma vaccine",
    "GVAX allogeneic myeloma vaccine",
    "allogeneic myeloma vaccine with GM-CSF-secreting K562 cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/allogeneic-gm-csf-secreting-myeloma-vaccine/"
}